Glucagon-Like Peptide-1 (GLP) Companion Food And Nutrition Market Global Report 2026

The glucagon-like peptide-1 (GLP) companion food and nutrition market size has grown exponentially in recent years. It will grow from $3.2 billion in 2025 to $4.14 billion in 2026 at a compound annual growth rate (CAGR) of 29.2%. The growth in the historic period can be attributed to rising prevalence of obesity and type 2 diabetes globally, increasing adoption of pharmacological weight management therapies, growth in functional food and dietary supplement industry, early clinical success of GLP-1 receptor agonist drugs, increasing consumer awareness of metabolic health management.

The glucagon-like peptide-1 (GLP) companion food and nutrition market size is expected to see exponential growth in the next few years. It will grow to $11.66 billion in 2030 at a compound annual growth rate (CAGR) of 29.6%. The growth in the forecast period can be attributed to expansion of GLP-1 drug adoption for weight and diabetes care, rising demand for personalized nutrition and precision diet planning, growth of digital health and nutrition tracking platforms, increasing integration of food-tech and biotech innovations, expansion of preventive healthcare and metabolic wellness programs. Major trends in the forecast period include personalized metabolic nutrition planning for GLP-1 therapy support, satiety-enhancing functional food formulations with appetite regulation focus, low glycemic index meal systems designed for glucose stabilization, microbiome optimized dietary interventions for weight management support, protein enriched and nutrient dense GLP-1 companion diets for muscle preservation.

The increasing rate of obesity is expected to accelerate the growth of the glucagon-like peptide-1 (GLP) companion food and nutrition market going forward. Obesity is a medical condition characterized by an excessive accumulation of body fat that can adversely affect health and elevate the risk of diseases such as diabetes, cardiovascular disease, and hypertension. The rising prevalence of obesity is mainly driven by unhealthy eating habits, including excessive consumption of calorie-dense, processed, and sugary foods, along with insufficient levels of physical activity. Glucagon-like peptide-1 (GLP) companion food and nutrition contributes to obesity management by complementing GLP-1-based weight-loss therapies with high-protein and high-fiber nutritional formulations that promote satiety, reduce excessive food intake, and help maintain lean muscle mass during calorie restriction. For instance, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government body, between 2023 and 2024, an estimated 64.5% of adults aged 18 years and above in England were overweight or living with obesity, compared with 64.0% during 2022 to 2023. Therefore, the increasing rate of obesity is driving the growth of the oral glucagon-like peptide-1 (GLP) companion food and nutrition market.

Key companies operating in the glucagon-like peptide-1 (GLP) companion food and nutrition market are focusing on developing innovative nutritional support solutions, such as protein and fiber-enriched companion food combinations, to improve dietary balance, prevent muscle loss, and address potential nutrient deficiencies associated with GLP-1-based weight-loss therapies. Protein and fiber-enriched companion food combinations are specially formulated food products that contain increased levels of protein and dietary fiber to support nutrition, promote satiety, and improve digestive health, particularly for individuals with reduced food intake or specific nutritional requirements. For example, in February 2024, Herbalife Ltd., a US-based nutrition and wellness company, launched Herbalife GLP-1 Nutrition Companion, a range of food and supplement product combinations designed to support individuals using GLP-1 and other weight-loss medications. The product range includes protein shake-based formulations and fiber-enriched nutrition blends aimed at helping users fulfill daily nutritional needs while supporting muscle preservation and digestive health. The solution also incorporates community-based nutritional guidance through distributors to promote healthier eating practices during and after weight-loss treatment, supporting long-term lifestyle improvements beyond medication use.

In March 2023, WeightWatchers International Inc., a US-based wellness company, acquired Sequence Weekend Health Inc. for $132 million. Through this acquisition, WeightWatchers aims to transition from a traditional diet and weight-loss provider into a modern clinical weight-management platform. The company focuses on integrating prescription obesity treatments, including Glucagon Like Peptide-1 medications, through telehealth services and digital support tools. Sequence Weekend Health Inc. is a US-based clinical weight-loss and obesity care company that provides GLP-1 companion nutrition and weight-management support programs, including personalized nutrition guidance, protein and hydration targets, dietitian support, behavioral coaching, recipes, and GLP-1-specific lifestyle programs designed to complement GLP-1 medications.

Major companies operating in the glucagon-like peptide-1 (glp) companion food and nutrition market report are Nestlé S.A., Danone S.A., Arla Foods amba, Glanbia plc, Herbalife Ltd., BellRing Brands Inc., The Simply Good Foods Company.

North America was the dominating region in the glucagon-like peptide-1 (GLP) companion food and nutrition market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the glucagon-like peptide-1 (GLP) companion food and nutrition market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the glucagon-like peptide-1 (GLP) companion food and nutrition market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.